- Moleculin Biotech Inc MBRX announced that preclinical data regarding its next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023.
- The poster outlined results from the analysis of the pharmacokinetics of two formulations of Annamycin, liposome formulated drug product (L-ANN) and free Annamycin (ANN), in the liver in comparison with doxorubicin (DOX) and to determine its tumoricidal potential in a hepatocellular carcinoma (HCC) model in situ and experimental models of liver metastasis.
- Related: Moleculin Reveals Final Topline Data From European Study Of Annamycin In Leukemia Setting.
- ANN exhibited significantly higher accumulation in the liver parenchyma when compared to DOX (6-fold higher AUC values).
- Researchers observed clear inhibition of the subcutaneous tumor growth after systemic (IV) administration of L-ANN.
- Increased liver uptake of the drug directly affected the drug's activity in vivo.
- An encouraging activity of L-ANN was observed in orthotopic models. Significant inhibition of the tumor growth and extension of the survival of L-ANN-treated mice vs. vehicle-receiving animals was observed.
- L-ANN treatment resulted in an increase in survival in the CT26 colon cancer experimental metastasis animal model.
- A significant delay in tumor progression was also observed in the pancreatic cancer liver metastasis model in a separate experiment.
- MBRX shares have been volatile in trading, up 31% at one point before the circuit breaker halt.
- Price Action: MBRX shares are down 6.35% at $0.88 on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
